Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Experimental Determination of Checkpoint Adaptation by Mitotic Shake-Off and Microscopy.

Swift LH, Golsteyn RM.

Methods Mol Biol. 2018;1769:159-168. doi: 10.1007/978-1-4939-7780-2_10.

PMID:
29564823
2.

G2/M-Phase Checkpoint Adaptation and Micronuclei Formation as Mechanisms That Contribute to Genomic Instability in Human Cells.

Kalsbeek D, Golsteyn RM.

Int J Mol Sci. 2017 Nov 6;18(11). pii: E2344. doi: 10.3390/ijms18112344. Review.

3.

Emerging Anti-Mitotic Activities and Other Bioactivities of Sesquiterpene Compounds upon Human Cells.

Bosco A, Golsteyn RM.

Molecules. 2017 Mar 13;22(3). pii: E459. doi: 10.3390/molecules22030459. Review.

4.

Cancer cells that survive checkpoint adaptation contain micronuclei that harbor damaged DNA.

Lewis CW, Golsteyn RM.

Cell Cycle. 2016 Nov 16;15(22):3131-3145. Epub 2016 Sep 16.

5.

Cytotoxic amounts of cisplatin induce either checkpoint adaptation or apoptosis in a concentration-dependent manner in cancer cells.

Swift LH, Golsteyn RM.

Biol Cell. 2016 May;108(5):127-48. doi: 10.1111/boc.201500056. Epub 2016 Mar 9.

PMID:
26871414
6.

Measurement of Cdk1/Cyclin B Kinase Activity by Specific Antibodies and Western Blotting.

Lewis CW, Taylor RG, Golsteyn RM.

Methods Mol Biol. 2016;1342:337-48. doi: 10.1007/978-1-4939-2957-3_21.

PMID:
26254935
7.

Natural product extracts of the Canadian prairie plant, Thermopsis rhombifolia, have anti-cancer activity in phenotypic cell-based assays.

Kernéis S, Swift LH, Lewis CW, Bruyère C, Oumata N, Colas P, Ruchaud S, Bain J, Golsteyn RM.

Nat Prod Res. 2015;29(11):1026-34. doi: 10.1080/14786419.2014.979423. Epub 2014 Nov 25.

PMID:
25423141
8.

Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cells.

Swift LH, Golsteyn RM.

Int J Mol Sci. 2014 Feb 25;15(3):3403-31. doi: 10.3390/ijms15033403. Review.

9.

A western blot assay to measure cyclin dependent kinase activity in cells or in vitro without the use of radioisotopes.

Lewis CW, Taylor RG, Kubara PM, Marshall K, Meijer L, Golsteyn RM.

FEBS Lett. 2013 Sep 17;587(18):3089-95. doi: 10.1016/j.febslet.2013.08.003. Epub 2013 Aug 15.

10.

Human cells enter mitosis with damaged DNA after treatment with pharmacological concentrations of genotoxic agents.

Kubara PM, Kernéis-Golsteyn S, Studény A, Lanser BB, Meijer L, Golsteyn RM.

Biochem J. 2012 Sep 15;446(3):373-81. doi: 10.1042/BJ20120385.

11.

Synthesis of Cis-fused pyran indolocarbazole derivatives that inhibit FLT3 kinase and the DNA damage kinase, checkpoint kinase 1.

Perron-Sierra FM, Kucharkzyk N, Boucley C, Guyard-Daumas C, Sciberras S, Fouache C, Plantier S, Studeny A, Bossard C, Casara PJ, Golsteyn RM.

Anticancer Agents Med Chem. 2012 Mar;12(3):194-201.

PMID:
22044003
12.

Characterization of novel checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors.

Ferry G, Studeny A, Bossard C, Kubara PM, Zeyer D, Renaud JP, Casara P, de Nanteuil G, Wierzbicki M, Pfeiffer B, Prudhomme M, Leonce S, Pierré A, Boutin JA, Golsteyn RM.

Life Sci. 2011 Aug 15;89(7-8):259-68. doi: 10.1016/j.lfs.2011.06.010. Epub 2011 Jun 29.

PMID:
21736880
13.

An unusual DNA binding compound, S23906, induces mitotic catastrophe in cultured human cells.

Cahuzac N, Studény A, Marshall K, Versteege I, Wetenhall K, Pfeiffer B, Léonce S, Hickman JA, Pierré A, Golsteyn RM.

Cancer Lett. 2010 Mar 28;289(2):178-87. doi: 10.1016/j.canlet.2009.08.014. Epub 2009 Sep 15.

PMID:
19758748
14.

Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints.

Tao Y, Leteur C, Yang C, Zhang P, Castedo M, Pierré A, Golsteyn RM, Bourhis J, Kroemer G, Deutsch E.

Cell Cycle. 2009 Apr 15;8(8):1196-205. Epub 2009 Apr 16.

PMID:
19305158
15.

Synthesis and CHK1 inhibitory potency of Hymenialdisine analogues.

Parmentier JG, Portevin B, Golsteyn RM, Pierré A, Hickman J, Gloanec P, De Nanteuil G.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):841-4. doi: 10.1016/j.bmcl.2008.12.001. Epub 2008 Dec 7.

PMID:
19111462
16.

Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitors.

Marminon C, Anizon F, Moreau P, Pfeiffer B, Pierré A, Golsteyn RM, Peixoto P, Hildebrand MP, David-Cordonnier MH, Lozach O, Meijer L, Prudhomme M.

Mol Pharmacol. 2008 Dec;74(6):1620-9. doi: 10.1124/mol.108.049346. Epub 2008 Sep 2.

PMID:
18768386
17.

Pyrrolocarbazoles as checkpoint 1 kinase inhibitors.

Hénon H, Conchon E, Hugon B, Messaoudi S, Golsteyn RM, Prudhomme M.

Anticancer Agents Med Chem. 2008 Aug;8(6):577-97. Review.

PMID:
18690823
18.

A three-step synthesis from rebeccamycin of an efficient checkpoint kinase 1 inhibitor.

Anizon F, Golsteyn RM, Léonce S, Pfeiffer B, Prudhomme M.

Eur J Med Chem. 2009 May;44(5):2234-8. doi: 10.1016/j.ejmech.2008.05.023. Epub 2008 Jul 3.

PMID:
18602198
19.

Novel 5-azaindolocarbazoles as cytotoxic agents and Chk1 inhibitors.

Lefoix M, Coudert G, Routier S, Pfeiffer B, Caignard DH, Hickman J, Pierré A, Golsteyn RM, Léonce S, Bossard C, Mérour JY.

Bioorg Med Chem. 2008 May 1;16(9):5303-21. doi: 10.1016/j.bmc.2008.02.086. Epub 2008 Mar 4.

PMID:
18342518
20.

Synthesis, checkpoint kinase 1 inhibitory properties and in vitro antiproliferative activities of new pyrrolocarbazoles.

Conchon E, Anizon F, Aboab B, Golsteyn RM, Léonce S, Pfeiffer B, Prudhomme M.

Bioorg Med Chem. 2008 Apr 15;16(8):4419-30. doi: 10.1016/j.bmc.2008.02.061. Epub 2008 Mar 5.

PMID:
18321713
21.

Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway.

Vitale I, Galluzzi L, Vivet S, Nanty L, Dessen P, Senovilla L, Olaussen KA, Lazar V, Prudhomme M, Golsteyn RM, Castedo M, Kroemer G.

PLoS One. 2007 Dec 26;2(12):e1337.

22.

Phosphorylation of CDC25C at S263 controls its intracellular localisation.

Esmenjaud-Mailhat C, Lobjois V, Froment C, Golsteyn RM, Monsarrat B, Ducommun B.

FEBS Lett. 2007 Aug 21;581(21):3979-85. Epub 2007 Jul 23.

23.

Synthesis and biological activities of isogranulatimide analogues.

Hugon B, Anizon F, Bailly C, Golsteyn RM, Pierré A, Léonce S, Hickman J, Pfeiffer B, Prudhomme M.

Bioorg Med Chem. 2007 Sep 1;15(17):5965-80. Epub 2007 Jun 7.

PMID:
17582773
24.
25.

Bis-imide granulatimide analogues as potent Checkpoint 1 kinase inhibitors.

Hénon H, Messaoudi S, Anizon F, Aboab B, Kucharczyk N, Léonce S, Golsteyn RM, Pfeiffer B, Prudhomme M.

Eur J Pharmacol. 2007 Jan 12;554(2-3):106-12. Epub 2006 Oct 19.

PMID:
17134696
26.

Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of indolylpyrazolones and indolylpyridazinedione.

Conchon E, Aboab B, Golsteyn RM, Cruzalegui F, Edmonds T, Léonce S, Pfeiffer B, Prudhomme M.

Eur J Med Chem. 2006 Dec;41(12):1470-7. Epub 2006 Sep 22.

PMID:
16996169
27.

Synthesis and biological activities of 7-aza rebeccamycin analogues bearing the sugar moiety on the nitrogen of the pyridine ring.

Messaoudi S, Anizon F, Peixoto P, David-Cordonnier MH, Golsteyn RM, Léonce S, Pfeiffer B, Prudhomme M.

Bioorg Med Chem. 2006 Nov 15;14(22):7551-62. Epub 2006 Aug 4.

PMID:
16889964
28.

Generation of replication-dependent double-strand breaks by the novel N2-G-alkylator S23906-1.

Léonce S, Kraus-Berthier L, Golsteyn RM, David-Cordonnier MH, Tardy C, Lansiaux A, Poindessous V, Larsen AK, Pierré A.

Cancer Res. 2006 Jul 15;66(14):7203-10.

29.

Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment.

Borgne A, Versteege I, Mahé M, Studeny A, Léonce S, Naime I, Rodriguez M, Hickman JA, Meijer L, Golsteyn RM.

Oncogene. 2006 Nov 30;25(56):7361-72. Epub 2006 Jun 19.

PMID:
16785996
30.

Synthesis and biological evaluation of new dipyrrolo[3,4-a:3,4-c]carbazole-1,3,4,6-tetraones, substituted with various saturated and unsaturated side chains via palladium catalyzed cross-coupling reactions.

Hénon H, Anizon F, Golsteyn RM, Léonce S, Hofmann R, Pfeiffer B, Prudhomme M.

Bioorg Med Chem. 2006 Jun 1;14(11):3825-34. Epub 2006 Feb 3.

PMID:
16460946
31.

Gefitinib does not increase survival in lung cancer patients.

Golsteyn RM.

Drug Discov Today. 2005 Mar 15;10(6):381. No abstract available.

PMID:
15808815
32.

Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle.

Golsteyn RM.

Cancer Lett. 2005 Jan 20;217(2):129-38. Review.

PMID:
15617830
33.

Recent advances in cancer research.

Golsteyn RM.

Drug News Perspect. 2004 Jul-Aug;17(6):405-16.

PMID:
15334191
34.

The story of gefitinib, an EGFR kinase that works in lung cancer.

Golsteyn RM.

Drug Discov Today. 2004 Jul 15;9(14):587. No abstract available.

PMID:
15239971
35.

The role of cyclin-dependent kinases in apoptosis.

Borgne A, Golsteyn RM.

Prog Cell Cycle Res. 2003;5:453-9. Review.

PMID:
14593740
36.

The dynamics of actin-based motility depend on surface parameters.

Bernheim-Groswasser A, Wiesner S, Golsteyn RM, Carlier MF, Sykes C.

Nature. 2002 May 16;417(6886):308-11.

PMID:
12015607
37.

ActA and human zyxin harbour Arp2/3-independent actin-polymerization activity.

Fradelizi J, Noireaux V, Plastino J, Menichi B, Louvard D, Sykes C, Golsteyn RM, Friederich E.

Nat Cell Biol. 2001 Aug;3(8):699-707.

PMID:
11483954
38.

The position of Chk1 in cancer research.

Golsteyn RM.

Trends Cell Biol. 2001 May;11(5):191. No abstract available.

PMID:
11316593
39.

When being right is not enough.

Golsteyn RM.

Trends Cell Biol. 2001 Feb;11(2):59. No abstract available.

PMID:
11166212
40.

Characterization of the interaction between zyxin and members of the Ena/vasodilator-stimulated phosphoprotein family of proteins.

Drees B, Friederich E, Fradelizi J, Louvard D, Beckerle MC, Golsteyn RM.

J Biol Chem. 2000 Jul 21;275(29):22503-11.

41.

Growing an actin gel on spherical surfaces.

Noireaux V, Golsteyn RM, Friederich E, Prost J, Antony C, Louvard D, Sykes C.

Biophys J. 2000 Mar;78(3):1643-54.

42.

LPP, an actin cytoskeleton protein related to zyxin, harbors a nuclear export signal and transcriptional activation capacity.

Petit MM, Fradelizi J, Golsteyn RM, Ayoubi TA, Menichi B, Louvard D, Van de Ven WJ, Friederich E.

Mol Biol Cell. 2000 Jan;11(1):117-29.

43.

Duration of pregnancy and risk of breast cancer.

Lapillonne H, Golsteyn RM, Lapillonne A.

Lancet. 1999 Jun 12;353(9169):2075. No abstract available.

PMID:
10376653
44.

Quantitative measurement of proteins by western blotting with Cy5-coupled secondary antibodies.

Fradelizi J, Friederich E, Beckerle MC, Golsteyn RM.

Biotechniques. 1999 Mar;26(3):484-6, 488, 490 passim.

PMID:
10090990
45.

Following comets

Golsteyn RM.

Curr Biol. 1998 Apr 23;8(9):R297-8. No abstract available.

46.

The role of actin binding proteins in epithelial morphogenesis: models based upon Listeria movement.

Golsteyn RM, Louvard D, Friederich E.

Biophys Chem. 1997 Oct;68(1-3):73-82.

PMID:
9468611
47.

On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression.

Mundt KE, Golsteyn RM, Lane HA, Nigg EA.

Biochem Biophys Res Commun. 1997 Oct 20;239(2):377-85.

PMID:
9344838
48.
49.

The family of polo-like kinases.

Golsteyn RM, Lane HA, Mundt KE, Arnaud L, Nigg EA.

Prog Cell Cycle Res. 1996;2:107-14. Review.

PMID:
9552388

Supplemental Content

Loading ...
Support Center